Porat Ruth has disclosed several stock transactions involving shares of Blackstone Inc., a prominent player in the investment advice sector. This filing, submitted on November 12, 2026, reveals the nature of her recent investments and their implications for her financial strategy.
Background
Porat Ruth is associated with Blackstone Inc. (CIK: 0001393818), a leading firm in the investment advice industry, classified under the SIC code 6282. The company operates primarily in the finance sector and is listed under the trading symbol BX. Recent filings show that Ruth has been actively managing her investments, as evidenced by multiple Form 4 submissions.
What the Filing Says
The recent Form 4 filing indicates that Ruth engaged in multiple stock transactions on November 9, 2026. Specifically, she acquired 126.507 shares at a price of $119.9245 each, 242.5149 shares at $121.3769, and 84.338 shares at $119.9245. Following these transactions, her total ownership rose to 42,557.9823 shares. The filing notes, "These shares were purchased in connection with a dividend reinvestment through brokerage accounts." Additionally, it states that some securities are held by a family limited partnership, where Ruth serves as a general partner.
Impact
This disclosure may affect various stakeholders, including investors and analysts monitoring Blackstone Inc.'s stock performance. Ruth's active trading may prompt discussions about executive investment strategies and their implications for corporate governance. As a director at Blackstone, her transactions could also influence investor perceptions of the company's leadership and financial health.
What's Next
The filing does not say what happens next.
Read Next
Jones Randall L Reports Ownership Change in Ashford Trust
Sherif Riad Reports Ownership Change at Ocular Therapeutix
Haiman Reports Ownership in Braemar Hotels & Resorts Inc.
Azora Therapeutics reports ownership change in SEC filing
Bain Capital Specialty Finance updates ownership structure
Habtezion Aida files ownership report for Azora Therapeutics







